



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: ANDERSON, DARRELL R., *et al.*

Serial No.:

Group Art Unit:

Filed: 13 November 1992

Examiner:

Title: THERAPEUTIC APPLICATION OF
CHIMERIC ANTIBODY TO HUMAN B
LYMPHOCYTE RESTRICTED
DIFFERENTIATION ANTIGEN FOR
TREATMENT OF B-CELL LYMPHOMA

13 November 1992
La Jolla, CA

**DECLARATION PURSUANT TO
37 C.F.R. §1.821(f)**

Commissioner of Patents and Trademarks
Washington, DC 20231

Sir:

I hereby declare that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1,821 (c) and (e), are the same.

Respectfully submitted,

Richard P. Burgoin, Jr.
Reg. No. 34,787
Intellectual Property Counsel
Registration No. 34,787
IDEC Pharmaceuticals Corporation
11099 North Torrey Pines Road, #160
La Jolla, CA 92037



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: ANDERSON, DARRELL R., *et al.*

Serial No.

Group Art Unit:

Filed: 13 November 1992

Examiner:

Title: THERAPEUTIC APPLICATION OF
CHIMERIC ANTIBODY TO HUMAN B
LYMPHOCYTE RESTRICTED
DIFFERENTIATION ANTIGEN FOR
TREATMENT OF B CELL LYMPHOMA

13 November 1992
La Jolla, CA

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR
1.9(f) and 1.27(c)) - SMALL BUSINESS CONCERN**

I hereby declare that I am

- () the owner of the small business concern identified below:
- (X) an official of the small business concern empowered to act on behalf
of the concern identified below:

NAME OF CONCERN: IDEC Pharmaceuticals Corporation

ADDRESS OF CONCERN: 11099 N. Torrey Pines Road, Suite 160
La Jolla, CA 92037

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Sections 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party of parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled: THERAPEUTIC APPLICATION OF CHIMERIC ANTIBODY TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR TREATMENT OF B CELL LYMPHOMA,

by inventors Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman and Mitchell E. Reff,

described in

- (X) the specification filed herewith
() application Serial No. _____, filed _____
() Patent No. _____, issued _____

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or a non-profit organization under 37 CFR 1.9(e). *NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

NAME N/A

ADDRESS _____

() INDIVIDUAL () SMALL BUSINESS CONCERN () NONPROFIT ORGANIZATION

NAME _____

ADDRESS _____

() INDIVIDUAL () SMALL BUSINESS CONCERN () NONPROFIT ORGANIZATION

NAME _____

ADDRESS _____

() INDIVIDUAL () SMALL BUSINESS CONCERN () NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: Kenneth J. Woolcott

TITLE OF PERSON OTHER THAN OWNER: General Counsel

ADDRESS OF PERSON SIGNING: 11099 N. Torrey Pines Road, La Jolla, CA 92037

SIGNATURE  DATE Nov. 12, 1992

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: ANDERSON, DARRELL R., *et al.*

Serial No.

Group Art Unit:

Filed: 13 November 1992

Examiner:

Title: THERAPEUTIC APPLICATION OF
CHIMERIC ANTIBODY TO HUMAN B
LYMPHOCYTE RESTRICTED
DIFFERENTIATION ANTIGEN FOR
TREATMENT OF B CELL LYMPHOMA

13 November 1992
La Jolla, CA

**COMBINED DECLARATION AND POWER OF ATTORNEY
IN PATENT APPLICATION**

As a below named inventor, I hereby declare that:

my residence, post office address and citizenship are as stated below next to my name;

I believe that I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled:

THERAPEUTIC APPLICATION OF CHIMERIC ANTIBODY TO HUMAN B
LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR TREATMENT
OF B CELL LYMPHOMA

the specification of which

(check one) X is attached hereto.

_____ was filed on _____ as Application Serial No.

_____ and was amended on _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information that is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) or patent or inventor's certificate listed below and have also identified below, any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s): N/A

			<u>Priority Claimed</u>
<u>Number</u>	<u>Country</u>	<u>Day/Month/Year Filed</u>	<u>Yes/No</u>
_____	_____	_____	_____
_____	_____	_____	_____
_____	_____	_____	_____

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

<u>Serial No.</u>	<u>Filing Date</u>	<u>Status (patented, pending, abandoned)</u>
_____	_____	_____
_____	_____	_____
_____	_____	_____

2. I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith: Kenneth J. Woolcott, Reg. No. 30,984, and Richard P. Burgoon, Jr., Reg. No. 34,787. Address all telephone calls to: Richard P. Burgoon, Jr., at telephone number (619) 458-0600.

Address all correspondence to:

Richard P. Burgoon, Jr.
Reg. No. 34,787
Intellectual Property Counsel
IDEC PHARMACEUTICALS CORPORATION
11099 North Torrey Pines Road, Suite 160
La Jolla, CA 92037

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-00
Darrell R. Anderson
Full Name of Inventor

United States
Citizenship

1851 Navato Place, Escondido, CA 92029
Residence

CA

Same as above
Post Office Address

Darrell R. Anderson
Inventor's Signature

Nov. 12, 1992
Date

2-00
Nabil Hanna
Full Name of Inventor

United States
Citizenship

3255 Fortuna Ranch Road, Olivenhain, CA 92024
Residence

CA

Same as above
Post Office Address

Nabil Hanna
Inventor's Signature

Nov. 12, 1992
Date

3-00
John E. Leonard
Full Name of Inventor

United States
Citizenship

1960 Avenida Joaquin, Encinitas, CA 92024
Residence

CA

Same as above
Post Office Address

John E. Leonard
Inventor's Signature

Nov. 12, 1992
Date

4-00
Roland A. Newman
Full Name of Inventor

United Kingdom
Citizenship

4311 Robbins Street, San Diego, CA 92122
Residence

CA

Same as above
Post Office Address

Roland A. Newman
Inventor's Signature

Nov. 12, 1992
Date

500

Mitchell E. Reff
Full Name of Inventor

United States
Citizenship

4166 Combe Way, San Diego, CA 92122
Residence

CA

Same as above
Post Office Address


Inventor's Signature

11/12/92
Date